Natco eyes U.S. FDA green light for Copaxone generic sales

India's Natco Pharma said all it needs is the approval from the U.S. FDA to launch a generic version of Teva's ($TEVA) Copaxone and put it on track to compete with versions from Sandoz, Momenta Pharmaceuticals and Mylan ($MYL). Last week, the U.S. Court of Appeals struck down the drug's patent for the second time, paving the way for companies to sell generic versions without the risk of having to pay Teva damages down the line from any new legal efforts. The multiple sclerosis drug has been at the center of furious efforts by Teva to protect its market share, including a new, long-acting version of the drug that the company hopes cements loyalty. Natco already sells a generic version in India under the brand Glatimer. Release (PDF)